Augustine Therapeutics

5 known investors

Augustine Therapeutics develops HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardiometabolic diseases. The company uses a novel non-hydroxamate chemotype approach to address therapeutic limitations in chronic disease treatment.